{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T17:13:15Z","timestamp":1722791595449},"reference-count":12,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recent years have brought major advances in the treatment of malignant melanoma. One such an advance is the treatment with BRAF tyrosine-kinase inhibitors in metastatic malignant melanomas that harbor mutations in the BRAF gene. The trials that have been performed in this setting have demonstrated superior response rates and increased overall survival, however, they mostly included patients with melanomas carrying the more common V600E and V600K mutations, not being able to assess the benefit of these treatments in situations where more rare mutations of the BRAF gene are present. We present the evolution of a patient with malignant melanoma with a rare V600M mutation in the BRAF gene, that was eventually treated with vemurafenib. Also we present a brief review of the major phase III trials that showed benefit with tyrosine-kinase inhibitors in BRAF mutated melanoma, with respect to the BRAF mutations included.<\/jats:p>","DOI":"10.1515\/rjim-2017-0044","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T22:16:05Z","timestamp":1511475365000},"page":"122-126","source":"Crossref","is-referenced-by-count":3,"title":["Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review"],"prefix":"10.1515","volume":"56","author":[{"given":"Andrei","family":"Popescu","sequence":"first","affiliation":[{"name":"Medical Oncology Department, \u201cColentina\u201d Clinical Hospital , Bucharest , Romania"},{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Haidar","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, \u201cColentina\u201d Clinical Hospital , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica Maricela","family":"Anghel","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy II, \u201cProf. Dr. Alexandru Trestioreanu\u201d Institute of Oncology , Bucharest , Romania"},{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"key":"2021040609500354113_j_rjim-2017-0044_ref_001_w2aab3b7b3b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. CHENG Y, ZHANG G, LI G. Targeting MAPK pathway in melanoma therapy. Cancer Metastasis Rev. 2013; 32(3\u20134):567-84.","DOI":"10.1007\/s10555-013-9433-9"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_002_w2aab3b7b3b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. DAVIES H, BIGNELL GR, COX C, STEPHENS P, EDKINS S, CLEGG S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54.","DOI":"10.1038\/nature00766"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_003_w2aab3b7b3b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. MALDONADO JL, FRIDLYAND J, PATEL H, JAIN AN, BUSAM K, KAGESHITA T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003; 95(24):1878-90.","DOI":"10.1093\/jnci\/djg123"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_004_w2aab3b7b3b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. VOSKOBOYNIK M, MAR V, MAILER S, et al. Clinico-pathological characteristics associated with BRAF(K) (601E) and BRAF(L) (597) mutations in melanoma. Pigment Cell Melanoma Res. 2016; 29 (2):222-8.","DOI":"10.1111\/pcmr.12450"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_005_w2aab3b7b3b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. CHAPMAN PB, HAUSCHILD A, ROBERT C, HAANEN JB, ASCIERTO P, LARKIN J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16.","DOI":"10.1056\/NEJMoa1103782"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_006_w2aab3b7b3b1b6b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. MCARTHUR GA, CHAPMAN PB, ROBERT C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. The Lancet Oncology. 2014; 15(3):323-332.10.1016\/S1470-2045(14)70012-9","DOI":"10.1016\/S1470-2045(14)70012-9"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_007_w2aab3b7b3b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. HAUSCHILD A, GROB JJ, DEMIDOV LV, JOUARY T, GUTZMER R, MILLWARD M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839):358-65.","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_008_w2aab3b7b3b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. LARKIN J, ASCIERTO PA, DRENO B, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med. 2014; 371:1867.","DOI":"10.1056\/NEJMoa1408868"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_009_w2aab3b7b3b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. LONG GV, STROYAKOVSKIY D, GOGAS H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386(9992):444-51.","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_010_w2aab3b7b3b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. ROBERT C, KARASZEWSKA B, SCHACHTER J, et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2015; 372:30-39","DOI":"10.1056\/NEJMoa1412690"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_011_w2aab3b7b3b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. PARAKH S, MURPHY C, LAU D, CEBON JS, ANDREWS MC. Response to MAPK pathway inhibitors in BRAF V600Mmutated metastatic melanoma. J Clin Pharm Ther. 2015; 40(1):121-3.","DOI":"10.1111\/jcpt.12229"},{"key":"2021040609500354113_j_rjim-2017-0044_ref_012_w2aab3b7b3b1b6b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. PONTI G, TOMASI A, PELLACANI G. Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. J Hematol Oncol. 2012; 5:60.","DOI":"10.1186\/1756-8722-5-60"}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/rjim\/56\/2\/article-p122.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/rjim-2017-0044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T09:52:31Z","timestamp":1617702751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/rjim-2017-0044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,5,17]]},"published-print":{"date-parts":[[2018,6,1]]}},"alternative-id":["10.1515\/rjim-2017-0044"],"URL":"https:\/\/doi.org\/10.1515\/rjim-2017-0044","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,17]]}}}